Jupiter Neurosciences, Inc.
JUNSW
NASDAQ Global Select- -
USD
- -
- -
CIK
0001679628
Return %
Stock
S&P500
1Y
- -
19.01
3Y
- -
65.48
5Y
- -
72.20
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Christer Rosen
- Full Time Employees
- 5
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1001 North US HWY 1 Jupiter FL United States of America 33477
- IPO Date
- Jan 18, 2022
- CIK
- 0001679628
- Website
- jupiterorphan.com
- Similar Companies
- Business
- Jupiter Neurosciences, Inc. operates as a clinical-stage pharmaceutical firm engaged in research and development, primarily focused on its proprietary resveratrol platform, JOTROL™. This innovative platform is designed to target neuroinflammation and mitochondrial dysfunction across a range of central nervous system disorders and rare diseases. JOTROL™ leverages a patented micellar technology to enhance the bioavailability of resveratrol more than nine-fold compared to conventional formulations, enabling it to reach therapeutic levels and effectively cross the blood-brain barrier without causing gastrointestinal side effects. The company's therapeutic pipeline includes JNS101, currently in Phase II trials for Friedreich's Ataxia, a rare neurological disorder, and JNS102, also in Phase II, addressing Mucopolysaccharidosis Type I. Furthermore, Jupiter Neurosciences is advancing JNS107 through Phase II studies for MELAS Syndrome and JNS108, which is in Phase II development for mild cognitive impairment and early Alzheimer's disease, supported by an ongoing NIH grant application. A significant recent development involves JNS115 for Parkinson's disease, which received FDA Investigational New Drug (IND) clearance in November 2025 to commence a Phase 2a clinical trial, with patient enrollment anticipated in early 2026. The company also maintains active development programs for JNS109 in amyotrophic lateral sclerosis, JNS110 for traumatic brain injury/concussion, and JNS120 for COVID-19 treatment. A strategic focus on targeting the NLRP3 inflammasome pathway underscores its approach to neurodegenerative conditions and aging. Beyond its pharmaceutical pipeline, Jupiter Neurosciences is expanding its business model by entering the consumer health sector with the upcoming launch of its Nugevia™ longevity product line in Q3 2025. These nutraceutical supplements, developed in partnership with Aquanova AG, will utilize the JOTROL™ platform to offer products aimed at mental wellness, mitochondrial energy, and skin vitality, establishing a direct-to-consumer revenue stream. The company secured up to $20 million in flexible financing in October 2025 and completed an $11 million Initial Public Offering on Nasdaq in December 2024. Formerly known as Jupiter Orphan Therapeutics, Inc., the entity adopted its current name in August 2021. Founded in 2016, Jupiter Neurosciences, Inc. is headquartered in Jupiter, Florida.